|
 Genzyme Corporation, a global leader in biotechnology, and the International Center for Genetic Engineering and Biotechnology (ICGEB), a not-for-profit research and development (R&D) organization, announced today a new research collaboration to advance treatments for neglected diseases. More›
|
 Genzyme Corporation today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase alfa) produced at the 2000 L bioreactor scale for the treatment of Late Onset Pompe disease. More›
|
 Genzyme and Osiris Therapeutics announced today that they have entered a strategic alliance for the development and commercialization of Prochymal and Chondrogen, two novel, late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases. More›
|
|
|